免疫疗法治疗重症新冠肺炎合理性及药学监护探讨

Rational Administration and Pharmaceutical Care of Drugs for Severe Patients with Coronavirus Disease 2019 Based on Immunotherapy

目的探讨免疫疗法治疗重型、危重型新型冠状病毒肺炎(COVID-19)的有效性和安全性,为合理用药及药学监护提供参考。方法查阅国内外文献,分析用于COVID-19重症感染患者免疫治疗的一线药物托珠单抗和糖皮质激素的作用机制、临床应用、注意事项、药学监护内容,针对个体差异给出合理用药及监护建议。结果与结论以托珠单抗和糖皮质激素为代表的免疫疗法治疗重型、危重型COVID-19有一定疗效,可缓解细胞因子风暴,临床应用中应严格把控药物使用指征、最佳剂量和疗程,针对特殊病理、生理人群需加强药学监护。

Objective To investigate the efficacy and safety of immunotherapy in the lteatment of severe and tritival patients with con-navirus disease 2019(CoVID-19),and to provide a eference for rational drug use and phamaceutical care.Methods The domesticand foreign literature was reviewed to analyze the mechanism of action,linical application,matters needing attention and pharmaceuticalcare of the fist-line drugs(tochizumab and glucocortioid)for immunotherapy in severe patients with COVID-19,anmd the rasonabledrug use and cae suggestions were given according to individual differences.Results and Conclusion lmmunotherapy represented bytochimmab and glucocortioid has a certain cuative effect in the treatment of severe and critical patients with COVID-19,which canalleviate the cytokine storm.In elinical application,the indicatioms,ptimal dosage and course of treatment should be strictly controlled,and pharmaceutical care should be strengthened for patients with special diseases and physiology.